Alpha-Lipoic Acid's Biggest Trial Yet Came Back Mixed. That Tracks.

The Oasis Health Journal · Submitted July 5, 2026 · 11:20 AM ET

Alpha-lipoic acid has been quietly clocked in inside spinach, broccoli, and your own mitochondria for a very long time. Scientists have spent about seventy years trying to figure out what it actually does there. The short version: it is an antioxidant with an unusually good resume, decades of use as a nerve-pain treatment in parts of Europe, and, as of this winter, a brand-new clinical trial that landed in the scientific equivalent of a shrug. It did not do the one thing researchers most wanted. It did do something nobody quite expected. That is more or less alpha-lipoic acid's entire career.

The Antioxidant That Recycles Its Coworkers

Alpha-lipoic acid (ALA) is made in small amounts by your own cells, where it helps mitochondria convert food into usable energy. It is also one of the few antioxidants that dissolves in both water and fat, so it can work in places vitamin C cannot reach and places vitamin E cannot reach, occasionally in the same afternoon. Its more interesting trick is recycling: ALA helps regenerate used-up vitamin C, which helps regenerate vitamin E, while also topping up glutathione, the antioxidant your cells treat like a master key. One ingredient, propping up three other defense systems. That kind of network effect is the whole idea behind most antioxidant formulas worth taking seriously.

The Old Job: Diabetic Nerve Pain

The oldest and best-documented use is diabetic peripheral neuropathy, the burning, tingling, and numbness that can follow years of elevated blood sugar. Alpha-lipoic acid has been used clinically for this in parts of Europe for decades, including as a prescription therapy in Germany, well before it showed up in US supplement aisles as an over-the-counter option. Oral trials have generally used 600 mg to 1,800 mg a day for up to six months, and intravenous dosing around 600 mg daily has also shown benefit for neuropathic symptoms in trial settings. If a nerve support supplement will not tell you its ALA dose, that is a fair question to ask before buying it.

The Honest Asterisk

Here is the part that keeps this from being a tidy success story. A 2024 Cochrane systematic review, the kind of rigorous analysis with no incentive to flatter anyone, pooled the accumulated trial data on ALA for diabetic neuropathy and rated the evidence low-certainty. Its conclusion: ALA may have little or no meaningful effect on nerve impairment scores at six months, though a real benefit could not be ruled out either. Decades of smaller, better-looking studies do not automatically survive contact with a Cochrane review, and this one is a useful reality check on the hype.

The New 2026 Plot Twist

Which brings us to this winter. Researchers at Oregon Health and Science University and the Portland VA ran a two-year, placebo-controlled trial of 1,200 mg daily ALA in 115 people with progressive multiple sclerosis, a form of the disease with very few treatment options. The logic was sound: MS involves oxidative damage to myelin, and ALA is a cheap, well-tolerated antioxidant that might slow it down. The primary outcome, walking speed, did not improve. The secondary outcome, brain atrophy measured by MRI, did: the ALA group lost less brain volume than the placebo group. The lead researcher called the results mixed and said she remains cautiously optimistic, partly because ALA has trouble crossing the blood-brain barrier in the first place, meaning a better-delivered version might do more. A larger international trial is already picking up the thread.

Where It Fits (and Where to Be Careful)

That MS trial also flagged something worth knowing: enrollment was paused at one point after two participants developed a kidney condition tied to combining ALA with other medications they were taking. On its own, alpha-lipoic acid is generally well tolerated, and studies have not turned up serious harm at doses up to 2,400 mg a day, with headache, heartburn, and nausea as the most common complaints. But it does lower blood sugar, which matters if you already use blood sugar support or diabetes medication, and it carries a specific warning for people with a thiamine (vitamin B1) deficiency, often linked to heavy alcohol use, where high doses have been associated with seizures. Loop in your doctor, especially if you take other medications. We carry alpha-lipoic acid sourced fresh per order rather than pulled off a warehouse shelf, on the theory that a molecule this reactive should not spend months losing potency before it reaches you. Slower shipping, fresher capsule. Worth the wait.

This article is for educational purposes only and is not medical advice. Talk to your healthcare provider before starting any supplement, especially if you take medication for diabetes, or have a thyroid condition or seizure disorder.

Sources

1. Mixed results in using lipoic acid to treat progressive multiple sclerosis, OHSU News
2. Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial, Neurology
3. Alpha-lipoic acid for diabetic peripheral neuropathy, Cochrane Database of Systematic Reviews
4. Alpha-Lipoic Acid, StatPearls, NCBI Bookshelf
5. Diabetic neuropathy: Can dietary supplements help?, Mayo Clinic
6. Diabetes and Dietary Supplements: What You Need To Know, NCCIH